ArticleFrontiers in oncology2022

Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies.

Hiroshi Nakatsumi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.